

Appendix D Angiotensin Receptor Blockers (ARBs)

Beneficial Subsets

- NYHA Class II-IV
- ARBs are not first-line agents and are reserved for patients intolerant of ACE-I or BB or for patients in NYHA class II and IV HF despite treatment with both ACE-I and BB

Contraindications, considerations, monitoring and dealing with side-effects

- See above – Same as ACE-I
- Note: Angioedema may recur with ARBs

| | STARTING DOSE | TARGET DOSE |
|--------------------------------------|---------------|--------------|
| Candesartan (Atacand [®]) | 4 mg daily | 32 mg daily |
| Valsartan (Diovan [®]) | 40 mg BID | 160 mg BID |
| Losartan (Cozaar [®]) | 25 mg daily | 100 mg daily |
| Telmisartan (Micardis [®]) | 40 mg daily | 80 mg daily |
| Irbesartan (Avapro [®]) | 75 mg daily | 300 mg daily |